News tagged with ms
Atrophy in key region of brain associated with multiple sclerosis
Magnetic resonance imaging (MRI) measurements of atrophy in an important area of the brain are an accurate predictor of multiple sclerosis (MS), according to a new study published online in the journal Radiology. According to the ...
Neuroscience
Apr 23, 2013 |
not rated yet |
1
Alternative medicine use by MS patients mapped
A major Nordic research project involving researchers from the University of Copenhagen has, for the first time ever, mapped the use of alternative treatment among multiple sclerosis patients - knowledge which is important ...
Diseases, Conditions, Syndromes
Apr 19, 2013 |
not rated yet |
0
'Unknown' neurological disorder often incorrectly diagnosed
The very serious hereditary disease HDLS was discovered in 1984 in Sweden. Many HDLS patients are still incorrectly diagnosed with Alzheimer's disease, MS or Parkinson's disease, but researchers at the Sahlgrenska Academy, ...
Neuroscience
Apr 10, 2013 |
not rated yet |
0
Major advance in understanding risky but effective multiple sclerosis treatment
A new study by Multiple Sclerosis researchers at three leading Canadian centres addresses why bone marrow transplantation (BMT) has positive results in patients with particularly aggressive forms of MS. The transplantation ...
Neuroscience
Mar 26, 2013 |
4.5 / 5 (2) |
0
Atrophy of the thalamus is an important predictor of clinically definite MS, study shows
A growing body of research by multiple sclerosis (MS) investigators at the University at Buffalo and international partners is providing powerful new evidence that the brain's gray matter reflects important ...
Neuroscience
Mar 21, 2013 |
5 / 5 (1) |
0
|
Researchers identify a promising target for multiple sclerosis treatments
A team of basic and clinical scientists led by the University of Montreal Hospital Research Centre's (CRCHUM) Dr. Nathalie Arbour has opened the door to significantly improved treatments for the symptoms of Multiple Sclerosis ...
Immunology
Mar 19, 2013 |
5 / 5 (3) |
0
|
MS patients did not benefit from CCSVI intervention
The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis has found that the intervention, sometimes called the "liberation ...
Neuroscience
Mar 15, 2013 |
not rated yet |
0
|
Combination therapy provides similar clinical benefit as single drug treatment in MS
People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new ...
Neuroscience
Mar 11, 2013 |
not rated yet |
0
Common MS drugs taken together do not reduce relapse risk
A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While ...
Neuroscience
Mar 11, 2013 |
not rated yet |
0
Can hormone help treat multiple sclerosis long-term?
A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and ...
Neuroscience
Mar 10, 2013 |
not rated yet |
0
Low incidence of venous insufficiency in MS
Results of a study using several imaging methods showed that CCSVI (chronic cerebrospinal venous insufficiency) occurs at a low rate in both people with multiple sclerosis (MS) and non-MS volunteers, contrary to some previous ...
Neuroscience
Mar 07, 2013 |
1 / 5 (1) |
0
Elan moves to deter takeover bid
(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.
Other
Mar 04, 2013 |
not rated yet |
0
A proposed link between aging, autism, and oxidation
Like any factory, the body burns oxygen to get energy for its various needs. As a result, detrimental byproducts are released and our cells try to clean up shop with antioxidants. But as we age, this process ...
Medical research
Mar 04, 2013 |
4.3 / 5 (3) |
0
|
Cancer drug a possible treatment for multiple sclerosis
(Medical Xpress)—A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, which ...
Medical research
Feb 21, 2013 |
4 / 5 (1) |
0
|
High risk of cardiovascular diseases amongst Swedish-born and immigrant MS patients
A new study from Karolinska Institutet shows that patients with multiple sclerosis (MS) run a high risk of heart attack, stroke and heart failure, regardless of migration background. According to principal investigator Tahereh ...
Neuroscience
Feb 04, 2013 |
not rated yet |
0
MSNBC
MSNBC is a 24-hour cable news channel based in the United States and available in both the US and Canada. Its name is a combination of "MSN" and "NBC".
Msnbc.com, a separate company, is the news website for the NBC News family, featuring interactivity and multimedia plus original stories and video which augment the content from NBC News and partners.
Two partnerships with the names MSNBC and msnbc.com were founded in 1996 by Microsoft and General Electric's NBC unit, which is now NBC Universal. Although Microsoft and NBC shared operations of MSNBC cable at its founding, it was announced on December 23, 2005, that NBC Universal would purchase a majority stake in the television network, which left Microsoft with 18%. The two companies remain 50-50 partners in msnbc.com. MSNBC shares the NBC logo of a rainbow peacock with its sister channels NBC, CNBC and ShopNBC.
Critics and observers of the network say that MSNBC has become increasingly politically liberal compared with other networks, particularly in its prime-time lineup.
For more information about MSNBC, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
